INmune Bio Inc. - INMB STOCK NEWS

INmune Bio (NASDAQ: INMB) and OmniScience have partnered to implement Vivo, a genAI-powered clinical trial control tower, for INmune's global Phase 2 Alzheimer's disease trial. The AD02 trial has completed patient randomization with 208 participants, comprising 56% mild AD and 44% mild cognitive impairment patients.

Vivo unifies data from multiple sources including EDC, CTMS, PROs/COAs, labs, and safety databases, providing real-time insights for improved decision-making. Initial benefits include enhanced data quality through automatic discrepancy identification, improved COA visualization, and real-time decision support for patient enrollment. Top-line cognitive results are expected in Q2 2025.

INmune Bio has completed patient randomization in its Phase 2 trial for Early Alzheimer's Disease (AD02), with a total of 208 enrolled patients. The global, blinded trial focuses on patients with elevated neuroinflammation biomarkers, with 56% categorized as mild AD and 44% as MCI. The study utilizes XPro™, targeting glial cells to reduce neuroinflammation and improve brain function. The primary endpoint measures cognitive function changes after 24 weeks using EMACC and CDR-SB metrics. Top-line cognitive results are expected in the second quarter of 2025.

INmune Bio announced Q3 2024 financial results and business updates. Key highlights include completion of enrollment for Phase 2 Alzheimer's Disease trial with target of 201 patients, and positive interim analysis showing correlation between EMACC and CDR-SB cognitive measures. INKmune™ demonstrated safety and increased NK-Cell activity in prostate cancer trial. The company secured $13.0 million through securities purchase agreements and received a $2.5 million R&D rebate. Financial results show Q3 net loss of $12.1 million, with R&D expenses of $10.1 million. Cash position stands at $33.6 million as of September 30, 2024.

INmune Bio (NASDAQ: INMB) announced a webinar on November 7, 2024, titled 'Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials'. The event will feature experts discussing EMACC's development and advantages in assessing cognitive changes in early Alzheimer's Disease patients. Additionally, the company will present a poster at the Clinical Trial in Alzheimer's Disease (CTAD) conference in Madrid about EMACC's validation in Phase II trials.

The company is currently conducting a global Phase II trial using XPro™ in Early AD patients, focusing on those with neuroinflammation. The trial's primary endpoint measures cognitive function changes after 6 months using both EMACC and CDR-SB assessments.

INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various CNS diseases, including Alzheimer's Disease, where myelin loss compromises neuron function. The company expects to report top-line cognitive results from its Phase II Early AD patients trial in first half of 2025.

INmune Bio (NASDAQ: INMB) has announced it will host a conference call on October 31, 2024, at 4:30 PM EDT to discuss its third quarter 2024 financial results and provide a corporate update. The clinical-stage inflammation and immunology company, which focuses on microglial activation and neuroinflammation in Alzheimer's Disease, will make the call available via phone and webcast. A transcript will be provided approximately 24 hours after the call, and a replay will be accessible through November 7, 2024.

INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company focusing on Alzheimer's Disease (AD), has announced its participation in the upcoming Maxim Healthcare Virtual Summit. The event is scheduled for October 15-17, 2024.

INmune Bio's management will be presenting at the summit on October 15, 2024, at 12:20 PM Eastern Time. The presentation will take the format of a fireside chat, and the company will also be available for one-on-one virtual meetings with attendees. Interested parties can register for the webcast through the provided link.

This participation provides an opportunity for INmune Bio to showcase its work on targeting microglial activation and neuroinflammation as potential causes of Alzheimer's Disease to healthcare industry professionals and investors.

INmune Bio Inc. (NASDAQ: INMB) has completed enrollment for its Phase 2 trial in Early Alzheimer's Disease (AD). The global, blinded, randomized trial, known as AD02, focuses on patients with Early AD and biomarkers of elevated neuroinflammation. The company closed enrollment on September 27, 2024, after determining that ongoing screenings would meet the target of 201 patients. Patients currently in the screening process remain eligible, potentially leading to modest over-enrollment.

CJ Barnum PhD, VP of CNS Drug Development and AD02 trial leader, emphasized the significance of this milestone for INmune Bio, its partners, and trial participants. He noted that exceeding the 201-patient goal will enhance the trial's statistical power, expressing anticipation for the final study results.

INmune Bio Inc. (NASDAQ: INMB) has announced initial results from the first patient cohort in its Phase I/II trial of INKmune™, a Natural Killer (NK) cell therapy for metastatic Castration-Resistant Prostate Cancer (mCRPC). The trial, named CaRe PC, has shown excellent safety profile with all patients receiving treatment as out-patients without pre-medication. Even at the lowest dose, there is clear evidence of persistent immunologic effects.

Key findings include:

• Changes in phenotype and function of patients' NK cells
• Increase in circulating activated NK cells in 2 of 3 patients
• Increased NK cell function sustained for over 40 days after final infusion in all patients
• One patient showed a transient 21% decrease in PSA associated with increased NK cell activity

The second dosing cohort has completed, and the third cohort is expected to begin in about 30 days, with doses 3 and 5 times higher than the first cohort, respectively.